PARR Clonality Testing: Uses and Important Limitations

PARR examines lymphocyte clonality and can support selected lymphoma or leukemia investigations, but it is not a stand-alone yes-or-no cancer test.

The assay amplifies rearranged antigen-receptor genes to assess whether lymphocytes appear predominantly clonal or diverse. It can be performed on several sample types, including some archived tissue, but sample selection and tumor proportion affect results.

It may help when morphology is suspicious but not definitive, when flow cytometry is equivocal or impractical, or when a formalin-fixed specimen needs ancillary assessment. Results should answer a pathologist- or oncologist-defined question.

Its value is highest when the result answers a defined question and would change diagnosis, staging, treatment, anesthesia, supportive care, or the recheck plan. Testing without a decision pathway can add cost or uncertainty without helping the patient.

The veterinary team selects timing, sample type, preparation, laboratory or imaging method, and repetition interval for the individual patient. Ask how this result will be interpreted alongside examination findings, pathology, prior results, medicines, and current symptoms.

University laboratory data and published validation support PARR in specific settings while documenting false-negative and false-positive limitations. Clonality is not synonymous with malignancy, and lack of detected clonality does not exclude it.

Physical risk depends on sample collection. The larger risk is misclassification from low tumor content, degraded DNA, an unsuitable tissue, reactive clonal expansion, prior treatment, or interpretation without morphology and clinical context.

A normal result cannot rule out every tumor or complication, and an abnormal result does not by itself identify the cause. Collection quality, timing, prior treatment, sedation, and laboratory or operator variation can affect interpretation.